Care precautions
Mebendazole
Treatment in Pregnancy
Mebendazole is a pregnancy category C drug. Data on the use of mebendazole in pregnant women are limited. The available evidence suggests no difference in congenital anomalies in the children of women treated with mebendazole during mass drug administration (MDA) campaigns compared with those who were not. In MDA campaigns in countries where soil-transmitted helminths are common, World Health Organization (WHO) has determined that the benefits of treatment outweigh the risks and WHO allows use of mebendazole in the 2nd and 3rd trimesters of pregnancy. However, in a pregnant woman infected with a soil-transmitted helminth, balance the risks of treatment for the fetus with the risks of disease progression in the woman in the absence of treatment.
Pregnancy Category C: Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal, or other) plus there are no controlled studies in women, or studies in women and animals are not available. Prescribe mebendazole only if the potential benefits to the woman justify the potential risks to the fetus.
Bạn đang xem: Clinical Overview of Pinworm infection
Treatment during lactation
Mebendazole is minimally excreted in breast milk. WHO classifies mebendazole as compatible with breastfeeding and allows its use in lactating women.
Treatment in pediatric patients
The safety of mebendazole in children is unclear. There are limited data in children under 2 years old. The WHO Model List of Essential Medicines for Children lists mebendazole as an intestinal anthelminthic medicine that can be used for children older than 2 years of age.
Pyrantel Pamoate
Treatment in Pregnancy
Xem thêm : Vómitos
Pyrantel pamoate is a pregnancy category C drug. Data on the use of ivermectin in pregnant women are limited. In mass drug administration (MDA) campaigns for which the World Health Organization (WHO) has determined that the benefits of treatment outweigh the risks, WHO allows use of pyrantel pamoate in the 2nd and 3rd trimesters of pregnancy. However, in a pregnant woman infected with a soil-transmitted helminth, balance the risks of treatment for the fetus with the risks of disease progression in the woman the absence of treatment.
Pregnancy Category C: Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal, or other) plus there are no controlled studies in women, or studies in women and animals are not available. Prescribe pyrantel pamoate only if the potential benefits justify the potential risks to the fetus.
Treatment during lactation
It is not known whether pyrantel pamoate is excreted in breast milk. The WHO classifies pyrantel pamoate as compatible with breastfeeding, although data on the use of pyrantel pamoate during lactation are limited.
Treatment in pediatric patients
The safety of pyrantel pamoate in children is unclear. According to the WHO guidance on preventative chemotherapy, children aged one year and older may use pyrantel during MDA campaigns without diagnosis. The WHO Model List of Essential Medicines for Children lists pyrantel pamoate as an intestinal anthelminthic medicine that can be use in children one year of age and older.
Albendazole
Treatment in Pregnancy
Xem thêm : Mal
Albendazole is a pregnancy category C drug. There are limited data on the use of albendazole in pregnant women. The available evidence suggests no difference in congenital abnormalities in the children of women accidentally treated with albendazole during mass drug administration (MDA) campaigns compared with those who were not. In MDA campaigns for which the World Health Organization (WHO) has determined that the benefits of treatment outweigh the risks, WHO allows use of albendazole in the 2nd and 3rd trimesters of pregnancy. However, healthcare providers should balance the risks of treatment for the fetus with the risks of disease progression in the woman in the absence of treatment.
Pregnancy Category C: Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal, or other) plus there are no controlled studies in women, or studies in women and animals are not available. Prescribe albendazole only if the potential benefits to the woman justify the potential risks to the fetus.
Treatment during lactation
Albendazole is minimally excreted in human milk. WHO has concluded that a single oral dose of albendazole can be given to lactating women.
Treatment in pediatric patients
The safety of albendazole in children less than 6 years old is not certain. Studies of the use of albendazole in children as young as one year old suggest that it is safe. According to WHO guidelines for MDA campaigns, children as young as one year of age (able to safely swallow tablets) can take albendazole. These campaigns have treated many children under six years old with albendazole, albeit at a reduced dose.
Nguồn: https://buycookiesonline.eu
Danh mục: Info
